logo
Share SHARE
FONT-SIZE Plus   Neg

Transcept Pharma Receives $10 Mln Milestone Payment From Purdue - Quick Facts

Transcept Pharmaceuticals Inc. (TSPT) said Wednesday it received a $10 million milestone payment from Purdue Pharma LP in connection with the listing of Intermezzo formulation patents in the FDA Orange Book on December 15, 2011.

The milestone payment was made under the terms of the agreement between Purdue and Transcept for the commercialization of insomnia drug Intermezzo in the US. Purdue plans to launch Intermezzo in the second quarter of 2012 and to invest about $100 million to support marketing during the first year of commercialization.

On November 23, 2011, the FDA approved Intermezzo (zolpidem tartrate) sublingual tablet C-IV for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.

Transcept reported cash, cash equivalents and marketable securities of $54.1 million at September 30, 2011, and excludes the $10 million payment received today.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Seattle police caught an alleged car thief by remotely locking him inside the stolen BMW 550i with the help of the automaker. The Seattle Police Department said in its blog that the incident took place in Seattle in November. United Airlines' new ticket option called 'Basic Economy,' which would require travelers to pay extra fees for using overhead bins, has been termed by New York Senator Charles Schumer as "one of the most restrictive policies on airline passengers seen in a long time." Schumer said that United Airlines should scrap its plan. United Airlines' new ticket option called 'Basic Economy,' which would require travelers to pay extra fees for using overhead bins, has been termed by New York Senator Charles Schumer as "one of the most restrictive policies on airline passengers seen in a long time." Schumer said that United Airlines should scrap its plan.
comments powered by Disqus
Follow RTT